Discrimination of agonist and antagonist forms of CXCL10 in biological samples

Clinical and Experimental Immunology

Volumn 167, Issue 1, 2012, Pages 137-148

  Casrouge, A ^a,b   Bisiaux, A ^a,b   Stephen, L ^f   Schmolz, M ^f   Mapes, J ^f   Pfister, C ^e   Pol, S ^b,c,d   Mallet, V ^b,c,d   Albert, M L ^a,b,c  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CNRS ^*  (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f Rules Based Medicine   (United States)

Author keywords

BCG; Bladder cancer; Chemokines monokines; Hepatitis C virus

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE RECEPTOR AGONIST; CYTOKINE RECEPTOR ANTAGONIST; DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ADULT; AGED; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BIOASSAY; BLADDER CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUBERCULOSIS; URINALYSIS; VIRUS CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BODY FLUIDS; CARCINOMA, TRANSITIONAL CELL; CHEMOKINE CXCL10; CULTURE MEDIA, CONDITIONED; DIPEPTIDYL PEPTIDASE 4; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOENZYME TECHNIQUES; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 82655181548     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04488.x     Document Type: Article

References (70)

1. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89:207-15.
2. Liu M, Guo S, Hibbert JM etal. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011; 22:121-30.
3. Taub DD, Longo DL, Murphy WJ. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 1996; 87:1423-31.
4. Angiolillo AL, Sgadari C, Taub DD etal. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182:155-62.
5. Christensen JE, de Lemos C, Moos T, Christensen JP, Thomsen AR. CXCL10 is the key ligand for CXCR3 on CD8+ effector T cells involved in immune surveillance of the lymphocytic choriomeningitis virus-infected central nervous system. J Immunol 2006; 176:4235-43.
6. Kaplan G, Luster AD, Hancock G, Cohn ZA. The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. J Exp Med 1987; 166:1098-108.
7. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166:1084-97.
8. Apolinario A, Majano PL, Lorente R, Nunez O, Clemente G, Garcia-Monzon C. Gene expression profile of T-cell-specific chemokines in human hepatocyte-derived cells: evidence for a synergistic inducer effect of cytokines and hepatitis C virus proteins. J Viral Hepatol 2005; 12:27-37.
9. Harvey CE, Post JJ, Palladinetti P etal. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74:360-9.
10. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003; 46:255-66.
11. Hensbergen PJ, van der Raaij-Helmer EM, Dijkman R etal. Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity. Eur J Biochem 2001; 268:4992-9.
12. van Heteren JT, Rozenberg F, Aronica E, Troost D, Lebon P, Kuijpers TW. Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in Aicardi-Goutieres syndrome. Glia 2008; 56:568-78.
13. Quint JK, Donaldson GC, Goldring JJ, Baghai-Ravary R, Hurst JR, Wedzicha JA. Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest 2010; 137:812-22.
14. Hsieh MF, Lai SL, Chen JP etal. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol 2006; 177:1855-63.
15. Chen JP, Lu HL, Lai SL etal. Dengue virus induces expression of CXC chemokine ligand 10/IFN-gamma-inducible protein 10, which competitively inhibits viral binding to cell surface heparan sulfate. J Immunol 2006; 177:3185-92.
16. Campanella GS, Tager AM, Khoury JKE etal. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci USA 2008; 105:4814-19.
17. Jain V, Armah HB, Tongren JE etal. Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malaria J 2008; 7:83-98.
18. Smoller BR, McNutt NS, Gray MH, Krueger J, Hsu A, Gottlieb AB. Detection of the interferon-gamma-induced protein 10 in psoriasiform dermatitis of acquired immunodeficiency syndrome. Arch Dermatol 1990; 126:1457-61.
19. Harlin H, Meng Y, Peterson AC etal. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009; 69:3077-85.
20. Kondo T, Nakazawa H, Ito F etal. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97:780-6.
21. Arenberg DA, Kunkel SL, Polverini PJ etal. Interferon-gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184:981-92.
22. Casrouge A, Decalf J, Ahloulay M etal. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011; 121:308-17.
23. Romero AI, Lagging M, Westin J etal. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006; 194:895-903.
24. Nakaya I, Wada T, Furuichi K etal. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron Exp Nephrol 2007; 107:e12-21.
25. Lazzeri E, Rotondi M, Mazzinghi B etal. High CXCL10 expression in rejected kidneys and predictive role of pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy. Transplantation 2005; 79:1215-20.
26. Heresi GA, Aytekin M, Newman J, Dweik RA. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung 2010; 188:191-7.
27. Nance S, Cross R, Fitzpatrick E. Chemokine production during hypersensitivity pneumonitis. Eur J Immunol 2004; 34:677-85.
28. Muller M, Carter S, Hofer MJ, Campbell IL. Review: the chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum. Neuropathol Appl Neurobiol 2010; 36:368-87.
29. Lacotte S, Brun S, Muller S, Dumortier H. CXCR3, inflammation, and autoimmune diseases. Ann NY Acad Sci 2009; 1173:310-17.
30. Schwartz TW, Frimurer TM, Holst B, Rosenkilde MM, Elling CE. Molecular mechanism of 7TM receptor activation - a global toggle switch model. Annu Rev Pharmacol Toxicol 2006; 46:481-519.
31. Rosenkilde MM, Andersen MB, Nygaard R, Frimurer TM, Schwartz TW. Activation of the CXCR3 chemokine receptor through anchoring of a small molecule chelator ligand between TM-III, -IV, and -VI. Mol Pharmacol 2007; 71:930-41.
32. Van den Steen PE, Husson SJ, Proost P, Damme JV, Opdenakker G. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 2003; 310:889-96.
33. Loos T, Mortier A, Gouwy M etal. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008; 112:2648-56.
34. Van den Steen PE, Deroost K, Van Aelst I etal. CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol 2008; 38:1082-95.
35. Oravecz T, Pall M, Roderiquez G etal. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997; 186:1865-72.
36. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 2005; 108:277-92.
37. Ludwig A, Schiemann F, Mentlein R, Lindner B, Brandt E. Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J Leukoc Biol 2002; 72:183-91.
38. Proost P, Schutyser E, Menten P etal. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98:3554-61.
39. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961-6.
40. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-72.
41. Butera D, Marukian S, Iwamaye AE etal. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005; 106:1175-82.
42. Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr 2007; 45:262-8.
43. Antonelli A, Ferri C, Fallahi P etal. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 2008; 57:1270-7.
44. Schmolz M, Hurst TL, Bailey DM etal. Validation of a new highly standardised, lab-independent whole-blood leukocyte function assay for clinical trials (ILCS). Exp Gerontol 2004; 39:667-71.
45. Poppas DP, Pavlovich CP, Folkman J etal. Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 1998; 52:268-75. discussion 75-6.
46. Bisiaux A, Thiounn N, Timsit MO etal. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette-Guerin therapy in patients with superficial bladder cancer. J Urol 2009; 181:1571-80.
47. Slimane TA, Lenoir C, Sapin C, Maurice M, Trugnan G. Apical secretion and sialylation of soluble dipeptidyl peptidase IV are two related events. Exp Cell Res 2000; 258:184-94.
48. Stefanovic V, Ardaillou N, Vlahovic P, Placier S, Ronco P, Ardaillou R. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993; 80:465-70.
49. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chim Acta 2006; 369:179-87.
50. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245:194-205.
51. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24:971-83.
52. Lopez-Otin C, Overall CM. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002; 3:509-19.
53. Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007; 14:675-87.
54. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-54.
55. Khakoo SI, Thio CL, Martin MP etal. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-4.
56. Lechner F, Wong DK, Dunbar PR etal. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191:1499-512.
57. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436:946-52.
58. Martin-Fontecha A, Thomsen LL, Brett S etal. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5:1260-5.
59. Mattern T, Scholz W, Feller AC, Flad HD, Ulmer AJ. Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes. Scand J Immunol 1991; 33:737-48.
60. Darling JM, Aerssens J, Fanning G etal. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011; 53:14-22.
61. Lagging M, Romero AI, Westin J etal. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44:1617-25.
62. Lambeir AM, Proost P, Durinx C etal. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001; 276:29839-45.
63. Firneisz G, Lakatos PL, Szalay F. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol 2001; 36:877-80.
64. Yang SS, Fu LS, Chang CS, Yeh HZ, Chen GH, Kao JH. Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 2006; 21:1789-93.
65. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116:180-3.
66. Luo Y, Chen X, O'Donnell MA. Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007; 147:370-8.
67. Rakoczi G, Takacs L, Jakabfi P etal. Increased urinary dipeptidyl peptidase IV activity in extrahepatic biliary atresia. Lancet 1995; 345:864-5.
68. Mitic B, Lazarevic G, Vlahovic P, Rajic M, Stefanovic V. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail 2008; 30:896-903.
69. Perner F, Gyuris T, Rakoczy G etal. Dipeptidyl peptidase activity of CD26 in serum and urine as a marker of cholestasis: experimental and clinical evidence. J Lab Clin Med 1999; 134:56-67.
70. Proost P, Mortier A, Loos T etal. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007; 110:37-44.